XT
SKYE icon

XTX Topco’s Skye Bioscience SKYE Stock Holding History

XTX Topco’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.6K Sell
2,624
-2,491
-49% -$15.7K ﹤0.01% 3971
2026
Q1 		$25.1K Sell
5,115
-1,515
-23% -$9.88K ﹤0.01% 3493
2025
Q4 		$39.8K Buy
+6,630
New +$77.5K ﹤0.01% 2889

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

XTX Topco's SKYE Position: Q2 2026 in Review

XTX Topco reduced its Skye Bioscience (SKYE) stake by 49% in Q2 2026, selling an estimated $15.7K and leaving 2,624 shares worth $14.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3971.

XTX Topco first reported a position in SKYE in Q4 2025 and has held it in 3 quarters since. The position peaked at $39.8K in Q4 2025. 33 funds tracked by Wall St. Rank hold SKYE as of Q2 2026.

  • XTX Topco held 2,624 shares of Skye Bioscience worth $14.6K as of Q2 2026.
  • XTX Topco sold 2,491 Skye Bioscience shares in Q2 2026, an estimated $15.7K.
  • Skye Bioscience made up ﹤0.01% of XTX Topco's portfolio in Q2 2026, its #3971 holding.
  • XTX Topco first reported a position in Skye Bioscience in Q4 2025 and has held it in 3 quarters since.
  • XTX Topco's Skye Bioscience position peaked at $39.8K in Q4 2025.
  • 33 funds tracked by Wall St. Rank held Skye Bioscience as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.